Sickle Cell Anemia Breakthrough: Targeting HbS, HbF, and Oxygenation with Next-Gen Carriers
BHOC – Biological Hemoglobin Oxygen Carrier shared a post on LinkedIn:
”HbS, HbF and Oxygenation in Sickle Cell Disease: A New Playbook With BHOC
HbS = The Saboteur
A single mutation → sickled cells → blocked vessels → pain and tissue damage. Severity is directly proportional to HbS levels.
HbF = The Natural Defender
Keep HbF above 20–30% and sickling is suppressed at the molecular level. Fewer crises, less cumulative organ damage.
Oxygenation = The Silent Hero
HbS polymerizes only when deoxygenated. Stabilizing oxygenated HbS—as voxelotor attempts—reduces sickling. Sustainable, side-effect-free approaches are still needed.
BHOCs = The Game Changer
Next-generation Blood Hemoglobin-Based Oxygen Carriers (BHOCs) deliver oxygen precisely where it’s needed—intervening before polymerization occurs.
Clinical evidence is still developing, but the concept is scientifically sound. Properly designed trials are key.
About future possibility
- BHOC can serve as a bridge to recovery. We believe it can transform the approach to Sickle Cell Anemia (SCA) treatment by providing supportive, low-volume infusion therapy before HbS levels become critical.
Much like insulin regulates blood sugar and HbA1c levels, BHOC can help support and control HbS polymerization levels, stabilizing oxygen delivery and patient condition.
Call to Action
- Stop just managing crises. Start preventing them. Let’s explore early warning systems integrating:
SaO₂, PaO₂, CaO₂, Hb, HbS polymerization levels — measurable with existing devices. Let’s act before the crisis hits.
Contact us for collaboration or discussion about clinical applications and partnerships.
Stay informed with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals